An On-Demand Collaborative Innate-Adaptive Immune Response to Infection Treatment

Adv Mater. 2024 Apr;36(15):e2304774. doi: 10.1002/adma.202304774. Epub 2024 Jan 17.

Abstract

Deep tissue infection is a common clinical issue and therapeutic difficulty caused by the disruption of the host antibacterial immune function, resulting in treatment failure and infection relapse. Intracellular pathogens are refractory to elimination and can manipulate host cell biology even after appropriate treatment, resulting in a locoregional immunosuppressive state that leads to an inadequate response to conventional anti-infective therapies. Here, a novel antibacterial strategy involving autogenous immunity using a biomimetic nanoparticle (NP)-based regulating system is reported to induce in situ collaborative innate-adaptive immune responses. It is observed that a macrophage membrane coating facilitates NP enrichment at the infection site, followed by active NP accumulation in macrophages in a mannose-dependent manner. These NP-armed macrophages exhibit considerably improved innate capabilities, including more efficient intracellular ROS generation and pro-inflammatory factor secretion, M1 phenotype promotion, and effective eradication of invasive bacteria. Furthermore, the reprogrammed macrophages direct T cell activation at infectious sites, resulting in a robust adaptive antimicrobial immune response to ultimately achieve bacterial clearance and prevent infection relapse. Overall, these results provide a conceptual framework for a novel macrophage-based strategy for infection treatment via the regulation of autogenous immunity.

Keywords: antibacterial immunotherapies; artificially reprogrammed cells; bacterial infections; immune recovery.

MeSH terms

  • Adaptive Immunity
  • Anti-Bacterial Agents / metabolism
  • Humans
  • Immunity, Innate*
  • Macrophages* / metabolism
  • Recurrence

Substances

  • Anti-Bacterial Agents